Novel Coronavirus 2019 (COVID-19): Analysis of the Emerging Disease Landscape - June 2020 Update - ResearchAndMarkets.com

·3-min read

The "Coronavirus Disease 2019 (COVID-19) - Analysis of the Emerging Disease Landscape - June 2020" report has been added to ResearchAndMarkets.com's offering.

The Epidemiology of COVID-19 is rapidly evolving and a number of companies have begun to invest in this space. The absence of proven therapeutic options and the lack of a vaccine to protect against infection has led to a race to develop effective interventions. A range of players - from pharma and biotech firms to academic institutions and government agencies - have thrown their hats in the ring.

Report Scope

  • Global epidemiology metrics and trends

  • Snapshot of epidemiological trends to date in the top three most-affected countries

  • An overview of the pipeline for antivirals and vaccines

  • Summary of available efficacy data

  • An assessment of the clinical trials landscape by phase, sponsor type, geography, and other key attributes

  • Highlights in deal-making trends, particularly public-private partnerships

  • Spotlight on social media coverage

Reasons to Buy

  • Understand the global epidemiology of COVID-19

  • Obtain a snapshot of epidemiological trends to date in the top three most-affected countries

  • Access an overview of the pipeline for therapeutics and vaccines

  • Stay up to date on available efficacy data for pipeline-stage products

  • View the clinical trials landscape by across key attributes

  • Get up to speed on highlights in deal-making trends, particularly public-private partnerships

  • Monitor top trends in social media coverage

Key Topics Covered

1 Executive Summary

2 Epidemiology

2.1 Epidemiology: Snapshot as of March 25, 2020

2.2 Epidemiology: Disease Trajectory as of March 25, 2020

2.3 Epidemiology Indicators in the Top 3 Most-Affected Countries: Disease Trajectory in China as of March 25, 2020

2.4 Epidemiology Indicators in the Top 3 Most-Affected Countries: Disease Trajectory in Italy as of March 25, 2020

2.5 Epidemiology Indicators in the Top 3 Most-Affected Countries: Disease Trajectory in the US as of March 25, 2020

2.6 Epidemiology Forecast: United States

3 Pipeline Overview

3.1 Pipeline Therapeutics: Breakdown by Phase

3.2 Pipeline Therapeutics: Breakdown by Molecule Type

3.3 Pipeline Therapeutics: Breakdown by Type of Developer

3.4 Pipeline Therapeutics: Clinical-Stage Candidates (Phase I - III)

3.5 Pipeline Therapeutics: Preclinical-Stage Candidates

3.6 Pipeline Therapeutics: Currently Available Data

3.7 Pipeline Vaccines: Breakdown by Phase

3.8 Pipeline Vaccines: Breakdown by Developer Type

3.9 Pipeline Vaccines: Clinical and Preclinical-Stage Candidates

4 Pipeline Overview

4.1 Pipeline Therapeutics: Breakdown by Phase

4.2 Pipeline Therapeutics: Breakdown by Molecule Type

4.3 Pipeline Therapeutics: Breakdown by Type of Developer

4.4 Pipeline Therapeutics: Clinical-Stage Candidates (Phase I - III)

4.5 Pipeline Therapeutics: Preclinical-Stage Candidates

4.6 Pipeline Therapeutics: Currently Available Data

4.7 Pipeline Vaccines: Breakdown by Phase

4.8 Pipeline Vaccines: Breakdown by Developer Type

4.9 Pipeline Vaccines: Clinical and Preclinical-Stage Candidates

5 Clinical Trials

5.1 Clinical Trials: Breakdown by Phase

5.2 Clinical Trials for Therapeutics and Vaccines

5.3 Clinical Trials: Overview by Region

5.4 Clinical Trials for Therapeutics: Leading Sponsors

5.5 Clinical Trials: Leading Industry Sponsors

5.6 Trends in Trial Design

6 Deal-making Trends

6.1 Deal-making Trends

7 Social Media Trends

7.1 Key Twitter Chatter

7.2 Top Trending Tweets include #Covid19 #Coronavirus #Patients #Flattenthecurve

8 Key Findings

For more information about this report visit https://www.researchandmarkets.com/r/87ymig

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200805005541/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900